Charles River Swoops on Early-stage CRO Citoxlab

Media Coverage
Chemist holding sample of liquid in laboratory

FierceBiotech

The takeover is the latest acquisition by Charles River in the last couple of years as it seeks to consolidate its position as a dominant player among early-stage contract research organizations (CROs). The company claims to have contributed to the R&D behind 80% of the FDA-approved drugs in 2017.

France-headquartered Citoxlab focuses on safety assessments and other nonclinical testing work such as drug discovery and medical device testing, and the company will contribute around $115 to $130 million to Charles River’s revenues this year.

Read the full story